ABBV-744 is BD2 specific - worth a read
|
10
|
Resverlogix Corp.
|
Feb 02, 2022 03:26PM
|
Re: The BET Protein Inhibitor Apabetalone Rescues Diabetes-induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1
|
9
|
Resverlogix Corp.
|
Dec 16, 2021 02:26PM
|
Re: Corporate Update Webcast and Conference Call December 16, 2021 @ 2 PM MST
|
4
|
Resverlogix Corp.
|
Dec 16, 2021 02:17PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
9
|
Resverlogix Corp.
|
Nov 29, 2021 06:14PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Nov 29, 2021 05:48PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
8
|
Resverlogix Corp.
|
Nov 29, 2021 05:46PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
12
|
Resverlogix Corp.
|
Nov 29, 2021 05:40PM
|
Yet another potential indication: Reduction of drug-seeking behavior
|
8
|
Resverlogix Corp.
|
Oct 26, 2021 03:12PM
|
Re: BETonMACE Cognition Sub-Study Published
|
4
|
Resverlogix Corp.
|
Sep 03, 2021 02:37PM
|
Re: BETonMACE Cognition Sub-Study Published
|
5
|
Resverlogix Corp.
|
Sep 01, 2021 12:26PM
|
Re: VOLUME
|
10
|
Resverlogix Corp.
|
Jun 30, 2021 06:26AM
|
Re: Short interest
|
2
|
Resverlogix Corp.
|
Apr 02, 2021 05:36PM
|
Short interest
|
1
|
Resverlogix Corp.
|
Apr 02, 2021 02:15PM
|
Re: 25% Pop in SP .... Now $1.12
|
7
|
Resverlogix Corp.
|
Mar 15, 2021 10:46AM
|
Re: Our own BKC on the webcast
|
8
|
Resverlogix Corp.
|
Feb 04, 2021 12:49PM
|
Re: Quote from a January 19, 2021 review
|
6
|
Resverlogix Corp.
|
Jan 21, 2021 03:46PM
|
Re: Quote from a January 19, 2021 review
|
12
|
Resverlogix Corp.
|
Jan 21, 2021 08:31AM
|
Quote from a January 19, 2021 review
|
12
|
Resverlogix Corp.
|
Jan 20, 2021 03:36PM
|
Re: RVX Announces Update Webcast and Conference Call
|
10
|
Resverlogix Corp.
|
Jan 18, 2021 01:26PM
|
Re: Odd
|
13
|
Resverlogix Corp.
|
Dec 08, 2020 04:31AM
|